| Safety, Tolerability, and Clinical Assessment of Bemdaneprocel for Parkinson’s Disease: 18-month Results from a Phase 1 Study (P9-3.007) C Henchcliffe, H Sarva, A Lozano, A Fasano, S Kalia, KKH Yu, C Brennan, ... Neurology 102 (17_supplement_1), 3382, 2024 | | 2024 |
| Imaging Outcomes of a Dopaminergic Neuronal Cell Therapy for Parkinson’s Disease: 18-month Results from a Phase 1 Study of Bemdaneprocel (S30. 005) C Henchcliffe, Y Ma, H Sarva, A Lozano, A Fasano, S Kalia, KKH Yu, ... Neurology 102 (17_supplement_1), 3326, 2024 | | 2024 |
| Non-motor Effects of Bemdaneprocel for Parkinson’s Disease: 18-month Results from a Phase 1 Study (P9-3.001) H Sarva, C Henchcliffe, A Lozano, S Kalia, KKH Yu, C Brennan, M York, ... Neurology 102 (17_supplement_1), 3521, 2024 | | 2024 |
| 510 Dopaminergic Neuronal Cell Therapy for Parkinson’s Disease: Results From a Phase 1 Study of Bemdaneprocel VS Tabar, K Yu, AM Lozano, CW Brennan, SK Kalia, A Fasano, H Sarva, ... Neurosurgery 70 (Supplement_1), 156, 2024 | 1 | 2024 |
| 390 Modelling Glioma Associated Macrophages Using Human Embryonic Stem Cell Derived Microglia K Hopland, KKH Yu, Z Abou Mrad, K Torckenczy, ED Bander, VS Tabar Neurosurgery 70 (Supplement_1), 118, 2024 | | 2024 |
| Transcript-specific enrichment enables profiling rare cell states via scRNA-seq T Abay, RR Stickels, MT Takizawa, BN Nalbant, YH Hsieh, S Hwang, ... bioRxiv, 2024 | | 2024 |
| Automated preparation of single nuclei from FFPE samples for snRNA-Seq S Jovanovich, N Pereira, D Meyer, C Snopkowski, I Masilionis, ... Cancer Research 84 (6_Supplement), 6840-6840, 2024 | | 2024 |
| Clinical and genomic characterization of melanoma brain metastases MP Mazzeo, HS Walch, R Kumar, J Eichholz, C Cooper, N Nandakumar, ... Cancer Research 84 (6_Supplement), 3785-3785, 2024 | | 2024 |
| THE GENOMIC LANDSCAPE OF BRAIN METASTASIS A Skakodub, H Walch, R Kumar, J Eichholz, C Cooper, I Khatri, ... NEURO-ONCOLOGY 25, 2023 | | 2023 |
| Orbital exenteration for craniofacial lesions: A systematic review and meta-analysis of patient characteristics and survival outcomes J Qedair, AS Haider, K Balasubramanian, P Palmisciano, T Hassan, ... Cancers 15 (17), 4285, 2023 | 2 | 2023 |
| Treatment and outcomes of IDH1-mutant gliomas in elderly patients AM Giantini-Larsen, Z Abou-Mrad, KY Kenny, AS Reiner, TA Bale, ... Journal of Neurosurgery 140 (2), 367-376, 2023 | 1 | 2023 |
| Genomic characterization of non-small cell lung cancer (NSCLC) brain metastasis (BM) patients identifies novel alterations associated with tropisms and disease progression H Walch, A Skakodub, KR Tringale, HN Vasudevan, J Eichholz, DW Kelly, ... Cancer Research 83 (7_Supplement), 6063-6063, 2023 | | 2023 |
| Characterization of Central Nervous System Clinico-Genomic Outcomes in ALK-Positive Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Alectinib E Miao, JE Eichholz, ES Lebow, J Flynn, Z Zhang, H Walch, H Hubbeling, ... Lung Cancer 178, 57-65, 2023 | 3 | 2023 |
| Tumors Involving the Infratemporal Fossa: A Systematic Review of Clinical Characteristics and Treatment Outcomes O Bin-Alamer, LS Bhenderu, K Balasubramanian, P Upadhyay, ... Journal of Neurological Surgery Part B: Skull Base 84 (S 01), P047, 2023 | | 2023 |
| Genomic analysis and clinical correlations of non-small cell lung cancer (NSCLC) brain metastasis (BM) A Skakodub, H Walch, K Tringale, J Eichholz, B Imber, H Vasudevan, B Li, ... | 4 | 2023 |
| Tumors involving the infratemporal fossa: a systematic review of clinical characteristics and treatment outcomes O Bin-Alamer, LS Bhenderu, P Palmisciano, K Balasubramanian, ... Cancers 14 (21), 5420, 2022 | 7 | 2022 |
| BIOM-01. GENOMIC ALTERATIONS IN ALK FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH BRAIN METASTASES J Eichholz, E Miao, E Lebow, H Walch, J Flynn, Z Zhang, H Hubbeling, ... Neuro-Oncology 24 (Supplement_7), vii3-vii3, 2022 | | 2022 |
| 347 Development of optimized CAR T cells for therapy of glioblastoma J Khan, W Cai, Y Yang, L Dong, K Hopland, KKH Yu, R Freeman, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| CNS Outcomes in ALK Fusion Positive NSCLC Patients with BM Who Received Alectinib with or without Local Therapy E Miao, ES Lebow, J Eichholz, J Flynn, Z Zhang, HG Hubbeling, K Beal, ... International Journal of Radiation Oncology, Biology, Physics 114 (3), e59-e60, 2022 | | 2022 |
| Neoadjuvant stereotactic radiotherapy for brain metastases: systematic review and meta-analysis of the literature and ongoing clinical trials P Palmisciano, G Ferini, R Khan, O Bin-Alamer, GE Umana, K Yu, ... Cancers 14 (17), 4328, 2022 | 7 | 2022 |
Ian Kamaly-AslConsultant Paeidatric Neurosurgeon, Royal Manchester Children's Hospital/University of Manchester在 nhs.net 的电子邮件经过验证
